Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
That is the crux of the re-rating argument and why the stock trades at a rich multiple
For more details on provincial health plan coverage see below: Alberta: Learn more about AHCIP here
FDA also announced on April 30, 2026 that it proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list
This increase on top of CBO's baseline would mean the 10-year Treasury yield could reach 4.9 percent by 2054, from 4.2 percent in 2025
Data sources: Bloomberg, Reuters, company regulatory filings, Health Canada ANDS database, CDSCO approvals, ANVISA records, SFDA notifications, PearceIP patent analysis, CEN Merck Index, company earnings calls and investor presentations
US$ 22.04
US$ 20.15
US$ 23.30
US$ 24.79
US$ 20.37
US$ 23.55
US$ 24.97
